Holen Sie sich die Stockscreener-App
15.32
4.31%
-0.69
Handel nachbörslich:
14.87
-0.45
-2.94%
Corvus Pharmaceuticals Inc Aktie (CRVS) Neueste Nachrichten
CRVS Stock Receives Analyst Rating and Price Target Boost from O - GuruFocus
Assessing Corvus Pharmaceuticals (CRVS) Valuation After Rapid Multi‑Year Share Price Gains - Yahoo Finance
According to the latest filing submitted to the U.S. Securities and Exchange Commission (SEC), Corvus Pharmaceuticals, Inc. has signed a revised equity distribution agreement. - Bitget
Corvus Pharmaceuticals Expands ATM Equity Program to $200 Million With Jefferies - TradingView
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q4 2025 Earnings Call Transcript - Insider Monkey
Corvus Pharmaceuticals (CRVS) files S-3 shelf to offer stock, debt, warrants - Stock Titan
Oppenheimer raises Corvus Pharmaceuticals stock price target to $33 By Investing.com - Investing.com Canada
Corvus Trials Progress And Cash Raise Reframe Soquelitinib Risk Reward Profile - simplywall.st
Corvus: Q4 Earnings Snapshot - theheraldreview.com
Decoding Corvus Pharmaceuticals Inc (CRVS): A Strategic SWOT Ins - GuruFocus
Corvus: Fourth Quarter Earnings Overview - Bitget
Earnings call transcript: Corvus Pharmaceuticals Q4 2025 Misses EPS Forecast - Investing.com
CRVS: Strong clinical and financial momentum with soquelitinib, supporting pipeline expansion and durability - TradingView
Corvus Pharmaceuticals Q4 Earnings Call Highlights - Yahoo Finance
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results - Bitget
Corvus Pharmaceuticals 2025 Financial Report: Quarterly & Annual Results | CRVSNews and StatisticsIndexBox - IndexBox - Market Intelligence Platform
Corvus Pharmaceuticals rises on atopic dermatitis trial data - Investing.com India
Corvus Pharmaceuticals rises on atopic dermatitis trial data By Investing.com - Investing.com Australia
CORVUS PHARMACEUTICALS ($CRVS) Releases Q4 2025 Earnings - Quiver Quantitative
Corvus Pharmaceuticals 10‑K: $0 Revenue, $(0.19) EPS (basic) — net loss $(15.28M) - TradingView
Corvus eczema drug posts positive early data and $189M cash boost - Stock Titan
Corvus Pharmaceuticals earnings on deck after positive trial data By Investing.com - Investing.com South Africa
Corvus Pharmaceuticals earnings on deck after positive trial data - Investing.com India
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Quarterly Earnings: Is Corvus Pharmaceuticals Inc being accumulated by smart money2026 Technical Overview & Free Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
Corvus Pharmaceuticals (CRVS) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Corvus Pharmaceuticals (CRVS) hits all-time high on eczema trial results - MSN
Fed Meeting: Does Corvus Pharmaceuticals Inc outperform in volatile marketsStop Loss & Fast Entry Momentum Alerts - baoquankhu1.vn
Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026 - The Manila Times
Corvus Pharmaceuticals (NASDAQ:CRVS) Stock Price Down 9.4%Here's Why - MarketBeat
Corvus Advances Soquelitinib Into Phase 2 Eczema Trial: What Investors Should Watch - TipRanks
Biotech Corvus sets March 12 call to discuss its 2025 results - Stock Titan
Does Corvus Pharmaceuticals’ (CRVS) Soquelitinib Focus Clarify Its Core Strategy or Concentration Risk? - simplywall.st
Market Recap: Is Corvus Pharmaceuticals Inc stock forming a cup and handle2025 Earnings Surprises & Consistent Return Investment Signals - baoquankhu1.vn
Assessing Corvus Pharmaceuticals (CRVS) Valuation After New Soquelitinib Trial Plans And Atopic Dermatitis Data - Sahm
Corvus Pharmaceuticals Highlights Soquelitinib Pipeline, Eyes Phase II Atopic Dermatitis Trial in 2026 - MarketBeat
Corvus Pharmaceuticals at Oppenheimer: Soquelitinib’s Promising Potential By Investing.com - Investing.com Canada
Corvus Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference - Yahoo Finance
Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Down 7.6%Time to Sell? - MarketBeat
Corvus Pharmaceuticals, Inc. $CRVS Shares Bought by GSA Capital Partners LLP - MarketBeat
Is Corvus Pharmaceuticals (CRVS) Still Attractive After Its Recent Share Price Surge - Yahoo Finance
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Corvus Pharmaceuticals (CRVS) Valuation Check After A Sharp Biotech Share Price Surge - Sahm
Is Corvus Pharmaceuticals (CRVS) Still Attractive After A 185% Monthly Surge? - simplywall.st
Corvus Pharmaceuticals (CRVS) price target increased by 128.26% to 35.70 - MSN
Stock Market Today, Jan. 20: Corvus Pharmaceuticals Surges After Positive Phase 1 Eczema Drug Data - AOL.com
Momentum Is Just Starting for These 3 Rapid-Growth Stocks in 2026 - Investing.com
Commit To Buy Corvus Pharmaceuticals At $8, Earn 20% Using Options - Nasdaq
Momentum Is Just Starting for These 3 Rapid-Growth Stocks in 2026 - The Globe and Mail
CRVS SEC FilingsCorvus Pharmaceu 10-K, 10-Q, 8-K Forms - Stock Titan
Assessing Corvus Pharmaceuticals (CRVS) Valuation After Recent Share Price Momentum - Sahm
Mizuho Raises Price Target on Corvus Pharmaceuticals to $30 From $20, Keeps Outperform Rating - marketscreener.com
Corvus Soquelitinib Data Spurs Phase 2 Plans And Fuels CRVS Reassessment - Sahm
Aug Selloffs: Why is Corvus Pharmaceuticals Inc. stock going downJuly 2025 Price Swings & Accurate Entry/Exit Alerts - mfd.ru
Will Corvus Pharmaceuticals Inc. benefit from rate cutsPrice Action & Low Risk Growth Stock Ideas - mfd.ru
Wall Street Analysts Think Corvus (CRVS) Could Surge 25.29%: Read This Before Placing a Bet - Your Wyoming Link
Corvus Pharmaceuticals Stock Rallies 209% in a Month: Here's Why - Finviz
Corvus Pharmaceuticals (CRVS) Is Up 211.80% in One Week: What You Should Know - Yahoo Finance
10 Big Names Stumbling Hard - Insider Monkey
Corvus Pharmaceuticals (CRVS) Falls on Profit-Taking After 212% Jump - Finviz
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):